{
    "ticker": "DRRX",
    "name": "DURECT Corporation",
    "description": "DURECT Corporation is a biopharmaceutical company focused on the development of innovative therapeutics for patients with unmet medical needs. Founded in 1998 and headquartered in Cupertino, California, DURECT is dedicated to creating new treatment options through its proprietary drug delivery technology and formulation expertise. The company's lead product candidate, DUR-928, is being investigated for its potential to treat various liver diseases, including non-alcoholic steatohepatitis (NASH) and acute alcoholic hepatitis. DURECT has also developed a range of other drug candidates targeting pain management and inflammation, leveraging its unique delivery systems to enhance the efficacy and safety of therapies. The company's commitment to research and development is evident in its partnerships with major pharmaceutical companies, which enable it to expand its pipeline and bring new therapies to market. DURECT is focused on improving patient outcomes by delivering innovative solutions that address significant medical challenges, thus positioning itself as a key player in the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cupertino, California, USA",
    "founded": "1998",
    "website": "https://www.durect.com",
    "ceo": "James E. Brown",
    "social_media": {
        "twitter": "https://twitter.com/DURECT_Corp",
        "linkedin": "https://www.linkedin.com/company/durect-corporation/"
    },
    "investor_relations": "https://investors.durect.com",
    "key_executives": [
        {
            "name": "James E. Brown",
            "position": "CEO"
        },
        {
            "name": "J. Michael McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "DUR-928",
                "DUR-001"
            ]
        },
        {
            "category": "Drug Delivery Systems",
            "products": [
                "SABER Technology",
                "Oral and Injectable Formulations"
            ]
        }
    ],
    "seo": {
        "meta_title": "DURECT Corporation | Innovative Therapeutics and Drug Delivery",
        "meta_description": "Learn about DURECT Corporation, a biopharmaceutical company developing innovative therapeutics and drug delivery systems for unmet medical needs.",
        "keywords": [
            "DURECT",
            "Biopharmaceuticals",
            "Drug Delivery",
            "Liver Disease",
            "DUR-928"
        ]
    },
    "faq": [
        {
            "question": "What does DURECT Corporation specialize in?",
            "answer": "DURECT Corporation specializes in the development of innovative therapeutics and drug delivery systems."
        },
        {
            "question": "Who is the CEO of DURECT Corporation?",
            "answer": "James E. Brown is the CEO of DURECT Corporation."
        },
        {
            "question": "Where is DURECT Corporation headquartered?",
            "answer": "DURECT Corporation is headquartered in Cupertino, California, USA."
        },
        {
            "question": "What are DURECT's main product candidates?",
            "answer": "DURECT's main product candidates include DUR-928 and DUR-001."
        },
        {
            "question": "When was DURECT Corporation founded?",
            "answer": "DURECT Corporation was founded in 1998."
        }
    ],
    "competitors": [
        "ALNY",
        "MRNA",
        "BMRN",
        "VRTX"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "NVAX"
    ]
}